Prestige Consumer Healthcare Reports Revenue Decline in Q2 Fiscal 2026

Prestige Consumer Healthcare Inc. reported a decline in financial performance for the second quarter of fiscal year 2026, with total revenues of $274.1 million for the three months ended September 30, 2025, down 3.4% from $283.8 million in the same period last year. The decrease was primarily driven by lower sales in the Eye & Ear Care and Women's Health categories, which were partially offset by growth in the Gastrointestinal segment. For the six months ended September 30, 2025, total revenues also fell to $523.6 million, a decrease of 5.0% compared to $550.9 million in the prior year.

The company's net income for the quarter was $42.2 million, a decrease of 22.3% from $54.4 million in the prior year, resulting in diluted earnings per share of $0.86, down from $1.09. For the six-month period, net income was $89.7 million, compared to $103.4 million in the previous year. The decline in profitability was attributed to increased costs and a higher effective tax rate, which rose to 38.9% from 24.1% year-over-year, largely due to establishing a taxable presence in a new state.

In terms of operational developments, Prestige Consumer Healthcare has continued to focus on its strategic growth initiatives, including product launches and acquisitions. The company has been actively managing its supply chain amid ongoing economic uncertainties, including inflation and global supply chain disruptions. As of September 30, 2025, the company reported cash and cash equivalents of $119.1 million, an increase from $97.9 million at the end of the previous fiscal year, reflecting improved cash flow from operations, which totaled $136.5 million for the six months ended September 30, 2025.

The company has also been engaged in share repurchase activities, having repurchased approximately 1.6 million shares for $109.8 million during the first half of the fiscal year. This is part of a broader strategy to enhance shareholder value, with $138.7 million remaining under its authorized repurchase program. Additionally, Prestige Consumer Healthcare has maintained a strong balance sheet, with total assets of $3.4 billion and total liabilities of $1.6 billion as of September 30, 2025.

Looking ahead, Prestige Consumer Healthcare anticipates continued challenges due to economic volatility and supply chain constraints, which may impact product availability and pricing. The company remains committed to leveraging its brand portfolio and distribution network to drive growth, while also adapting to changing consumer purchasing patterns, particularly the shift towards online sales. The management's outlook emphasizes a cautious approach, with ongoing evaluations of market conditions and operational efficiencies to navigate the evolving landscape.